Royalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) EV/FCF
As of 5 November 2026, Royalty Pharma PLC (RPRX) trades at a EV/FCF of 29.5×. Over the past ten years it has ranged from −161× (January 2021) to 214× (December 2020); the current reading is higher than 80% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 7.1× | 7.94% |
| FY2024 | 6.6× | 13.80% |
| FY2023 | 5.8× | (45.91%) |
| FY2022 | 10.7× | — |
| FY2021 | −124× | — |
| FY2020 | −154× | — |
| FY2019 | 18.6× | 0.00% |
| FY2018 | 18.6× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 26.3× | 4.32% |
| Jun 2026 | 25.3× | 3.03% |
| Mar 2026 | 24.5× | 245.88% |
| Dec 2025 | 7.1× | 4.71% |
| 25 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| INSM Insmed, Inc. compare | −37.2× |
| ROIV Roivant Sciences Ltd. compare | −28.1× |
| RVMD Revolution Medicines, Inc. compare | −25.0× |
| BNTX BioNTech SE Sponsored ADR compare | −9.6× |
| GMAB Genmab A/S Sponsored ADR compare | −5.7× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 27.1× |
| RPRX Royalty Pharma PLC | 29.5× |
| INCY Incyte Corporation compare | 29.7× |
| ARGX argenex SE compare | 38.4× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement